Advanced search
Publication Cover
Immunopharmacology and Immunotoxicology Volume 45, 2023 - Issue 5
Submit an article Journal homepage
159
Views
0
CrossRef citations to date
0
Altmetric
Review Articles

Evaluation of HER-2 positive breast cancer treated with dual-targeted treatment of trastuzumab plus pertuzumab

Shuai Jianga Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, ChinaORCID Iconhttps://orcid.org/0000-0003-1235-6269View further author information
ORCID Icon,
Shuai Gengb Department of Pharmacy, Strategic Support Force Medical Center, Beijing, ChinaView further author information
,
Xinyue Gaoa Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, ChinaView further author information
,
Tong Liua Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, ChinaView further author information
,
Xinyu Luoa Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, ChinaView further author information
,
Nan Wanga Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, ChinaView further author information
,
Ning Shib Department of Pharmacy, Strategic Support Force Medical Center, Beijing, ChinaCorrespondence[email protected]
View further author information
&
Mei Donga Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 616-625 | Received 03 Dec 2022, Accepted 10 Feb 2023, Published online: 13 Mar 2023

References

  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
  • Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300.
  • Exman P, Tolaney SM. HER2-positive metastatic breast cancer: a comprehensive review. Clin Adv Hematol Oncol. 2021;19(1):40–50.
  • Kunte S, Abraham J, Montero AJ. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer. 2020;126(19):4278–4288.
  • Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res. 2021;23(1):84.
  • Gan Y, Li L, Zhang L, et al. Association between shift work and risk of prostate cancer: a systematic review and meta-analysis of observational studies. Carcinogenesis. 2018;39(2):87–97.
  • Swain SM, Ewer MS, Cortés J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. The Oncologist. 2013;18(3):257–264. DOI:10.1634/theoncologist.2012-0448
  • Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–530.
  • Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-Positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial. JAMA Oncol. 2020; 6(3):e193692.
  • Xu B, Li W, Zhang Q, et al. Pertuzumab, trastuzumab, and docetaxel for chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res Treat. 2020;182(3):689–697.
  • Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800.
  • Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (neosphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32. DOI:10.1016/S1470-2045(11)70336-9. 22153890
  • Martin M, Fumoleau P, Dewar JA, et al. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. Ann Oncol. 2016;27(7):1249–1256.
  • Swain SM, Baselga J, Kim SB,, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. 513.
  • Piccart M, Procter M, Fumagalli D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer in the APHINITY trial: 6 years’ Follow-Up. J Clin Oncol. 2021;39(13):1448–1457.
  • Rimawi M, Ferrero JM, de la Haba-Rodriguez J, et al. First-Line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-Positive and hormone Receptor-Positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018; 36(28):2826–2835.
  • Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017; 389(10087):2415–2429.
  • Derakhshani A, Rezaei Z, Safarpour H, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol. 2020;235(4):3142–3156.
  • Ishii K, Morii N, Yamashiro H. Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. Core Evid. 2019;14:51–70.
  • Perez EA, Barrios C, Eiermann W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-Positive, advanced breast cancer: Primary results from the phase III MARIANNE study. J Clin Oncol. 2017;s35(2):141–148.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.